{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T09:08:26Z","timestamp":1788944906067,"version":"build-2803163510"},"reference-count":69,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell Dev. Biol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Current tumor classification systems based on histology and molecular subtypes inadequately capture the functional complexity of cancer biology. Tumors frequently reactivate embryonic developmental programs, becoming dependent on master regulators that govern pluripotency, differentiation and tissue morphogenesis. This developmental reactivation creates architectural vulnerabilities in gene regulatory networks that can be therapeutically exploited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We propose DNV-TC, a four-dimensional classification system that stratifies tumors according to the reactivated developmental program, network architectural vulnerability, cascade expansion phenotype and metastatic propensity. The system integrates developmental biology with network medicine through three quantitative indices computed on multi-layer gene regulatory networks: the tumor developmental regulatory impact (T-DRI), tumor disease network vulnerability (TD-NV) and cascade expansion index-tumor (CEI-T). DNV-TC was applied retrospectively to representative tumor types using published molecular and clinical data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Tumors with high network vulnerability showed marked responses to targeted therapies (87% response rate) but rapidly developed resistance (median 6\u20138 months), while tumors with reactivated pluripotency programs displayed cancer stem-cell characteristics and therapeutic resistance. Network vulnerability class retained independent prognostic value after adjustment for stage, grade and age (HR 2.3, 95% CI 1.8\u20132.9, p &amp;lt; 0.001), and metastatic propensity class outperformed TNM staging for 5-year metastasis-free survival prediction (AUC 0.842 versus 0.712, p &amp;lt; 0.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>DNV-TC provides a mechanistically grounded classification system that bridges developmental biology and precision oncology, thus enabling rational selection of therapeutic targets and combination strategies. The present analyses are retrospective and in silico, and prospective external validation is required.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcell.2026.1780827","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T08:37:25Z","timestamp":1788943045000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["DNV-TC: a developmental network vulnerability-based classification system for precision oncology"],"prefix":"10.3389","volume":"14","author":[{"given":"Draga","family":"Toncheva","sequence":"first","affiliation":[{"name":"Department of Biological Sciences, Bulgarian Academy of Sciences","place":["Sofia, Bulgaria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassil","family":"Sgurev","sequence":"additional","affiliation":[{"name":"Institute of Information and Communication Technologies, Bulgarian Academy of Sciences","place":["Sofia, Bulgaria"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/nrg2102","article-title":"Network motifs: theory and experimental approaches","volume":"8","author":"Alon","year":"2007","journal-title":"Nat. Rev. Genet."},{"key":"B3","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/nature05236","article-title":"Glioma stem cells promote radioresistance by preferential activation of the DNA damage response","volume":"444","author":"Bao","year":"2006","journal-title":"Nature"},{"key":"B4","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nrg1272","article-title":"Network biology: understanding the cell's functional organization","volume":"5","author":"Barab\u00e1si","year":"2004","journal-title":"Nat. Rev. Genet."},{"key":"B5","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/nrg2918","article-title":"Network medicine: a network-based approach to human disease","volume":"12","author":"Barab\u00e1si","year":"2011","journal-title":"Nat. Rev. Genet."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1038\/ng.465","article-title":"SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas","volume":"41","author":"Bass","year":"2009","journal-title":"Nat. Genet."},{"key":"B7","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/ng.127","article-title":"An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors","volume":"40","author":"Ben-Porath","year":"2008","journal-title":"Nat. Genet."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1200\/jco.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","volume":"34","author":"Bower","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrc1014","article-title":"Neuroblastoma: biological insights into a clinical enigma","volume":"3","author":"Brodeur","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/nejmoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1038\/onc.2015.174","article-title":"Role of HOXA9 in leukemia: dysregulation, cofactors and essential targets","volume":"35","author":"Collins","year":"2016","journal-title":"Oncogene"},{"key":"B12","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/nmeth.3440","article-title":"Pathway and network analysis of cancer genomes","volume":"12","author":"Creixell","year":"2015","journal-title":"Nat. Methods"},{"key":"B14","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1111\/j.1755-148X.2009.00578.x","article-title":"Frequent mutations in the microphthalmia-associated transcription factor gene (MITF) in human melanoma","volume":"22","author":"Cronin","year":"2009","journal-title":"Pigment Cell Melanoma Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1002\/cncr.25634","article-title":"Prognostic factors for survival in melanoma patients with brain metastases","volume":"117","author":"Davies","year":"2011","journal-title":"Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/s0140-6736(12)61963-1","article-title":"Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial","volume":"381","author":"Davies","year":"2013","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/nrurol.2018.22","article-title":"Cellular plasticity and the neuroendocrine phenotype in prostate cancer","volume":"15","author":"Davies","year":"2018","journal-title":"Nat. Rev. Urol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/nrc2943","article-title":"Acute promyelocytic leukaemia: novel insights into the mechanisms of cure","volume":"10","author":"de Th\u00e9","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1002\/(SICI)1098-1004(1999)13:6<464::AID-HUMU6>3.0.CO;2-A","article-title":"Mutations of the VHL gene in sporadic renal cell carcinoma: definition of a risk factor for VHL patients to develop an RCC","volume":"13","author":"Gallou","year":"1999","journal-title":"Hum. Mutat."},{"key":"B21","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1634\/stemcells.2008-0493","article-title":"SOX2 silencing in glioblastoma tumor-initiating cells causes stop of proliferation and loss of tumorigenicity","volume":"27","author":"Gangemi","year":"2009","journal-title":"Stem Cells"},{"key":"B22","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1038\/nm.3967","article-title":"The consensus molecular subtypes of colorectal cancer","volume":"21","author":"Guinney","year":"2015","journal-title":"Nat. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"B25","doi-asserted-by":"publisher","first-page":"C47","DOI":"10.1038\/35011540","article-title":"From molecular to modular cell biology","volume":"402","author":"Hartwell","year":"1999","journal-title":"Nature"},{"key":"B26","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"key":"B27","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.cell.2018.03.022","article-title":"Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer","volume":"173","author":"Hoadley","year":"2018","journal-title":"Cell"},{"key":"B28","doi-asserted-by":"publisher","first-page":"dju055","DOI":"10.1093\/jnci\/dju055","article-title":"US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status","volume":"106","author":"Howlader","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"key":"B29","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/bies.201100031","article-title":"The molecular and mathematical basis of Waddington's epigenetic landscape: a framework for Post-Darwinian biology?","volume":"34","author":"Huang","year":"2012","journal-title":"Bioessays"},{"key":"B30","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.semcdb.2009.07.003","article-title":"Cancer attractors: a systems view of tumors from a gene network dynamics and developmental perspective","volume":"20","author":"Huang","year":"2009","journal-title":"Semin. Cell Dev. Biol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/nature12634","article-title":"Mutational landscape and significance across 12 major cancer types","volume":"502","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"B33","doi-asserted-by":"publisher","first-page":"193","DOI":"10.4137\/grsb.s702","article-title":"Centrality analysis methods for biological networks and their application to gene regulatory networks","volume":"2","author":"Kosch\u00fctzki","year":"2008","journal-title":"Gene Regul. Syst. Bio."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.cell.2006.09.048","article-title":"GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland","volume":"127","author":"Kouros-Mehr","year":"2006","journal-title":"Cell"},{"key":"B35","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/msb.2010.31","article-title":"A human B-cell interactome identifies MYB and FOXM1 as master regulators of proliferation in germinal centers","volume":"6","author":"Lefebvre","year":"2010","journal-title":"Mol. Syst. Biol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/nature19057","article-title":"Analysis of protein-coding genetic variation in 60,706 humans","volume":"536","author":"Lek","year":"2016","journal-title":"Nature"},{"key":"B37","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/nejmoa1300874","article-title":"Retinoic acid and arsenic trioxide for acute promyelocytic leukemia","volume":"369","author":"Lo-Coco","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial","volume":"386","author":"Long","year":"2015","journal-title":"Lancet"},{"key":"B39","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s11060-011-0575-8","article-title":"The natural history of extracranial metastasis from glioblastoma multiforme","volume":"105","author":"Lun","year":"2011","journal-title":"J. Neurooncol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.cell.2017.01.018","article-title":"Clonal heterogeneity and tumor evolution: past, present, and the future","volume":"168","author":"McGranahan","year":"2017","journal-title":"Cell"},{"key":"B42","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1182\/blood-2008-07-168617","article-title":"Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors","volume":"113","author":"Montesinos","year":"2009","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/nature09626","article-title":"Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation","volume":"468","author":"Nazarian","year":"2010","journal-title":"Nature"},{"key":"B44","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41572-019-0063-6","article-title":"Medulloblastoma","volume":"5","author":"Northcott","year":"2019","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B45","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.tcb.2018.12.001","article-title":"EMT transition states during tumor progression and metastasis","volume":"29","author":"Pastushenko","year":"2019","journal-title":"Trends Cell Biol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"key":"B48","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/nature05349","article-title":"Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells","volume":"444","author":"Piccirillo","year":"2006","journal-title":"Nature"},{"key":"B49","doi-asserted-by":"publisher","first-page":"a008052","DOI":"10.1101\/cshperspect.a008052","article-title":"Wnt signaling in cancer","volume":"4","author":"Polakis","year":"2012","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1158\/2159-8290.CD-12-0418","article-title":"Targeting MYCN in neuroblastoma by BET bromodomain inhibition","volume":"3","author":"Puissant","year":"2013","journal-title":"Cancer Discov."},{"key":"B51","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.cell.2018.06.025","article-title":"Toward minimal residual disease-directed therapy in melanoma","volume":"174","author":"Rambow","year":"2018","journal-title":"Cell"},{"key":"B52","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.cell.2011.11.025","article-title":"EMT and dissemination precede pancreatic tumor formation","volume":"148","author":"Rhim","year":"2012","journal-title":"Cell"},{"key":"B53","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"B54","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B55","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1200\/JCO.2016.67.1487","article-title":"Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology Guideline","volume":"34","author":"Rugo","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"8554","DOI":"10.1073\/pnas.141230798","article-title":"Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation","volume":"98","author":"Sakamoto","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B57","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","article-title":"Oncogenic signaling pathways in the Cancer Genome Atlas","volume":"173","author":"Sanchez-Vega","year":"2018","journal-title":"Cell"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.critrevonc.2004.04.007","article-title":"Stem cell origin of cancer and differentiation therapy","volume":"51","author":"Sell","year":"2004","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1158\/2159-8290.CD-13-0642","article-title":"Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy","volume":"4","author":"Shi","year":"2014","journal-title":"Cancer Discov."},{"key":"B60","first-page":"143","article-title":"Network medicine approaches to the genetics of complex diseases","volume":"14","author":"Silverman","year":"2012","journal-title":"Discov. Med."},{"key":"B61","doi-asserted-by":"publisher","first-page":"10869","DOI":"10.1073\/pnas.191367098","article-title":"Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications","volume":"98","author":"S\u00f8rlie","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","article-title":"BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet","volume":"118","author":"Soverini","year":"2011","journal-title":"Blood"},{"key":"B63","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B64","doi-asserted-by":"publisher","first-page":"D941","DOI":"10.1093\/nar\/gky1015","article-title":"COSMIC: the catalogue of somatic mutations in cancer","volume":"47","author":"Tate","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"B65","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.cell.2009.11.007","article-title":"Epithelial-mesenchymal transitions in development and disease","volume":"139","author":"Thiery","year":"2009","journal-title":"Cell"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1200\/JCO.2008.17.5984","article-title":"Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034","volume":"27","author":"Van den Bent","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.1172\/JCI61269","article-title":"The molecular basis of T cell acute lymphoblastic leukemia","volume":"122","author":"Van Vlierberghe","year":"2012","journal-title":"J. Clin. Invest."},{"key":"B68","volume-title":"The Strategy of the Genes","author":"Waddington","year":"1957"},{"key":"B69","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1126\/science.1073096","article-title":"Cancer. Addiction to oncogenes-the Achilles heal of cancer","volume":"297","author":"Weinstein","year":"2002","journal-title":"Science"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/ng.2764","article-title":"The Cancer Genome Atlas Pan-Cancer analysis project","volume":"45","author":"Weinstein","year":"2013","journal-title":"Nat. Genet."},{"key":"B71","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s11060-006-9193-2","article-title":"Medical management of patients with brain tumors","volume":"80","author":"Wen","year":"2006","journal-title":"J. Neurooncol."}],"container-title":["Frontiers in Cell and Developmental Biology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2026.1780827\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T08:37:28Z","timestamp":1788943048000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2026.1780827\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":69,"alternative-id":["10.3389\/fcell.2026.1780827"],"URL":"https:\/\/doi.org\/10.3389\/fcell.2026.1780827","relation":{},"ISSN":["2296-634X"],"issn-type":[{"value":"2296-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]},"article-number":"1780827"}}